The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Camidanlumab tesirine for R/R non-Hodgkin or Hodgkin lymphomas
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, of Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the Phase I study (NCT02432235) evaluating the safety and efficacy of camidanlumab tesirine (Cami-T or ADCT-301), an antibody-drug conjugate, in patients with relapsed/refractory non-Hodgkin or Hodgkin lymphomas. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Collins discusses the promising results from this study, before stressing the need to find the optimal dose; maximizing efficacy, but minimizing the toxicity.
